Date | Price Target | Rating | Analyst |
---|---|---|---|
8/28/2024 | $35.00 | Overweight | Wells Fargo |
6/27/2024 | $29.00 | Sector Outperform | Scotiabank |
6/3/2024 | $20.00 | Underperform | Jefferies |
5/8/2024 | $25.00 → $35.00 | Market Perform → Outperform | Leerink Partners |
12/21/2023 | $23.00 | Neutral | Piper Sandler |
12/19/2023 | $20.00 | Equal Weight | Wells Fargo |
12/14/2023 | $23.00 | Buy | Guggenheim |
12/13/2023 | $28.00 | Outperform | Wolfe Research |
During the last three months, 4 analysts shared their evaluations of Myriad Genetics (NASDAQ:MYGN), revealing diverse outlooks from bullish to bearish. Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 0 2 1 1 0 Last 30D 0 1 0 0 0 1M Ago 0 0 0 1 0 2M Ago 0 1 1 0 0 3M Ago 0 0 0 0 0 The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $28.0, a high estimate of $35.00, and a low estimate of $20.00. Observing a 15.08% increase, the current average ha
SALT LAKE CITY, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ:MYGN), a leader in genetic testing and precision medicine, will host an Investor Event at the Westin Grand Central Hotel in New York City on October 9, 2024. The in-person event will commence at 9:00 am EDT and last approximately two hours. Paul J. Diaz, President and CEO, and other members of the Myriad executive leadership team will discuss the company's long-term growth strategy, operational initiatives, scientific and clinical advancements reflected in its product pipeline, and long-term financial goals. For those interested in attending the event in person, please register here. For those unable to att
SALT LAKE CITY, Aug. 21, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in genetic testing and precision medicine, today announced Myriad management will participate in two upcoming investor healthcare conferences. The Wells Fargo Healthcare Conference in a fireside chat featuring Scott Leffler, Chief Financial Officer, on Sept. 4, 2024 at 1:30pm ET.The Morgan Stanley Healthcare Conference in a fireside chat featuring Paul J. Diaz, President and CEO, on Sept. 5, 2024 at 7:00am ET. Links to the live and archived webcasts of both presentations can be viewed at investor.myriad.com. About Myriad GeneticsMyriad Genetics is a leading genetic testing and precision medic
Highlights Second quarter revenue grew 15% year-over-year to $212 million, driven by Prenatal (25%), Pharmacogenomics (22%), and Hereditary Cancer (19%).Second quarter GAAP earnings per share improved to $(0.41) from $(1.42) in the second quarter of 2023; adjusted earnings per share improved to $0.05 from $(0.08) in the second quarter of 2023.Increasing 2024 financial guidance with full year revenue moving to a range of $835 - $845 million, or an annual growth rate of between 11% and 12%, and increasing adjusted earnings per share (EPS) to a range of $0.08 - $0.12.1 _________________________1 The company does not forecast GAAP EPS because it cannot predict certain elements that are include
4 - MYRIAD GENETICS INC (0000899923) (Issuer)
4 - MYRIAD GENETICS INC (0000899923) (Issuer)
4 - MYRIAD GENETICS INC (0000899923) (Issuer)
8-K - MYRIAD GENETICS INC (0000899923) (Filer)
10-Q - MYRIAD GENETICS INC (0000899923) (Filer)
8-K - MYRIAD GENETICS INC (0000899923) (Filer)
Wells Fargo initiated coverage of Myriad Genetics with a rating of Overweight and set a new price target of $35.00
Scotiabank initiated coverage of Myriad Genetics with a rating of Sector Outperform and set a new price target of $29.00
Jefferies resumed coverage of Myriad Genetics with a rating of Underperform and set a new price target of $20.00
SC 13G - MYRIAD GENETICS INC (0000899923) (Subject)
SC 13G - MYRIAD GENETICS INC (0000899923) (Subject)
SC 13G - MYRIAD GENETICS INC (0000899923) (Subject)
SALT LAKE CITY, July 31, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in genetic testing and precision medicine, today announced the appointment of Jennifer Fox as Chief Legal Officer, effective September 3, 2024. Fox brings nearly two decades of legal experience in the life sciences sector. Her expertise spans intellectual property, litigation, and regulatory matters, gained through roles in both in-house and private practice settings at industry-leading companies. As Chief Legal Officer, Fox's responsibilities will encompass a wide range of areas, including support and counsel for all legal affairs, intellectual property, patent protection, mergers and acquis
SALT LAKE CITY, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ:MYGN), a leader in genetic testing and precision medicine, today announced the appointment of Dallas Reed, MD, FACOG, FACMG as Principal Medical Advisor to its women's health business unit, effective immediately. Dr. Reed brings nearly 15 years of clinical and academic experience rooted in genetics and obstetrics/gynecology to Myriad. In her new role, she will support internal and external efforts to increase access to, and equity around, genetic testing throughout a woman's health journey including family planning, pregnancy management and hereditary cancer risk assessment. "We're thrilled to welcome Dallas
SALT LAKE CITY, Jan. 30, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ:MYGN), a leader in genetic testing and precision medicine, today announced the appointment of George Daneker Jr., MD, as President and Chief Clinical Officer of Oncology, effective March 18, 2024. Dr. Daneker brings more than 30 years of oncology and precision medicine experience deeply rooted in providing accessible and equitable oncology care for all patients. In his new role, he will be responsible for leading the commercial and clinical strategy to advance Myriad's oncology portfolio, which currently offers germline testing, tumor profiling and companion diagnostic options, including homologous recombinat
Highlights Second quarter revenue grew 15% year-over-year to $212 million, driven by Prenatal (25%), Pharmacogenomics (22%), and Hereditary Cancer (19%).Second quarter GAAP earnings per share improved to $(0.41) from $(1.42) in the second quarter of 2023; adjusted earnings per share improved to $0.05 from $(0.08) in the second quarter of 2023.Increasing 2024 financial guidance with full year revenue moving to a range of $835 - $845 million, or an annual growth rate of between 11% and 12%, and increasing adjusted earnings per share (EPS) to a range of $0.08 - $0.12.1 _________________________1 The company does not forecast GAAP EPS because it cannot predict certain elements that are include
SALT LAKE CITY, July 30, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in genetic testing and precision medicine, will hold its second quarter earnings conference call on Tuesday, August 6, 2024 at 4:30pm ET. The company's quarterly earnings will be released the same day after the market closes. During the call, Myriad management will provide a financial overview and business update of the company's performance for the second quarter 2024. A live webcast of the earnings conference call can be accessed on Myriad's Investor Relations website at investor.myriad.com. To participate in the live conference call via telephone, please register here. Upon registering, a d
Highlights: First quarter revenue of $202 million grew 12% year-over-year, driven by Prenatal (22%), Pharmacogenomics (21%), and Hereditary Cancer (16%). First quarter average revenue per test improved by 2% over the prior year period, reflecting no-pay reduction efforts.First quarter GAAP net loss of $26 million and positive adjusted EBITDA of $4 million; net loss and adjusted EBITDA improved significantly from $55 million and $(19) million, respectively, in the first quarter of 2023.First quarter GAAP earnings per share and adjusted earnings per share of $(0.29) and $(0.01), respectively, improved significantly as compared to $(0.67) and $(0.21), respectively, in the first quarter of 20